Lifeboat Foundation

A global collaboration involving University of Manchester scientists has discovered a gene whose variants potentially cause neurodevelopmental disorders (NDDs) in hundreds of thousands of people across the world.

The findings of the University of Oxford led study, published in Nature, are an exciting first step towards the development of future treatments for the disorders which have devastating impacts on learning, behavior, speech, and movement.

While most NDDs are thought to be genetic and caused by changes to DNA, to date around 60% of individuals with the conditions do not know the specific DNA change that causes their disorder.

Human history can be seen as a catalogue of our technological pushback against nature. Our earliest technologies—including fire and clothing—enabled us to endure relentlessly harsh climates, and subsequent eras saw our creativity give birth to anesthetics, electricity, antibiotics, and vaccines.

How does cannabis alleviate the symptoms associated with chronic musculoskeletal (MSK) pain in patients? This is what a recent study published in the Journal of Cannabis Research hopes to address as a team of researchers from Canada investigated patient perception regarding cannabis use and treating their MSK symptoms. This study comes as an increasing number of MSK patients have turned to cannabis to alleviate their pain symptoms without hard data to support that use.

For the study, the researchers conducted a self-reported survey with 629 MSK patients in Canada with an average age of 56 years old and comprised of 44 percent men and 56 percent women. For the surveys, the patients were asked to privately disclose their past or present cannabis use in managing their MSK pain. In the end, 144 (23 percent) of participants reported past or present cannabis use with 63.7 percent disclosing that cannabis was effective at treating their MSK pain and 26.6 percent disclosing it as “slightly effective”, per the study.

The researchers concluded, “One in five patients presenting to an orthopaedic surgeon with chronic MSK pain are using or have used cannabis with the specific intent to manage their pain, and most report it to be effective. Among non-users, two-thirds reported an interest in using cannabis to manage their MSK pain, but common barriers to use existed. Future double-blind placebo-controlled trials are required to understand if this reported efficacy is accurate, and what role, if any, cannabis may play in the management of chronic MSK pain.”

Scientists have taken a significant step towards the development of tailor-made chiral nanocarriers with controllable release properties. These nanocarriers, inspired by nature’s helical molecules like DNA and proteins, hold immense potential for targeted drug delivery and other biomedical applications.

The study, led by Professors Emilio Quiñoá and Félix Freire at the Center for Research in Biological Chemistry and Molecular Materials (CiQUS), highlights the intricate relationship between the structure of helical polymers and their self-assembly into nanospheres. By carefully designing the secondary chain, the researchers were able to modulate the acidity of the polymers, influencing their aggregation patterns and leading to the formation of nanoespheres with varying densities.

Intriguingly, the size of these nanospheres could be precisely controlled by simply adjusting the water-to-solvent ratio during their preparation, eliminating the need for stabilizers. This eco-friendly approach paves the way for sustainable synthesis of these particles.

This study presents a discovery in the fight against hepatocellular carcinoma (HCC) by identifying the protein Schlafen 11 (SLFN11) as a key factor influencing the effectiveness of immune checkpoint inhibitors (ICIs). Through comprehensive analysis using humanized orthotopic HCC mouse models and in vitro co-culture systems, the research unveils how SLFN11’s deficiency in tumor cells leads to an increase in C-C motif chemokine ligand 2 (CCL2) secretion. This phenomenon promotes the infiltration of immunosuppressive macrophages and leads to immune evasion. The study also showcases the therapeutic potential of blocking CCL2/CCR2 signaling to enhance the efficacy of ICIs in patients with low SLFN11 expression. These findings pave the way for future research to explore additional therapeutic targets within the immune landscape of HCC, offering hope for more effective treatments and improved patient outcomes.

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, with advanced stages showing dismal survival rates due to limited treatment efficacy. The efforts to improve the situation have focused on immunotherapies, such as immune checkpoint inhibitors (ICIs), though their success varies significantly among individuals due to the complex interplay of tumor growth and immune evasion within the tumor microenvironment (TME). Previous studies have hinted at the role of tumor-associated macrophages (TAMs) and chemokines like CCL2 in the functional remodeling of TAMs. However, a comprehensive understanding of the mechanisms driving immune evasion and therapy resistance in HCC has been lacking. This research proposes a solution by identifying SLFN11’s role in modulating the immune landscape of HCC, specifically its influence on macrophage polarization and CCL2 signaling. The outcome offers new avenues for enhancing ICI therapy effectiveness.

Continue reading “Liver Cancer: How Tackling a Protein Could Boost Immunotherapy Success” »

While taking snapshots with the high-speed “electron camera” at the Department of Energy’s SLAC National Acceleratory Laboratory, researchers discovered new behavior in an ultrathin material that offers a promising approach to manipulating light that will be useful for devices that detect, control or emit light, collectively known as optoelectronic devices, and investigating how light is polarized within a material. Optoelectronic devices are used in many technologies that touch our daily lives, including light-emitting diodes (LEDs), optical fibers and medical imaging.

As reported in Nano Letters (“Giant Terahertz Birefringence in an Ultrathin Anisotropic Semimetal”), the team, led by SLAC and Stanford professor Aaron Lindenberg, found that when oriented in a specific direction and subjected to linear terahertz radiation, an ultrathin film of tungsten ditelluride, which has desirable properties for polarizing light used in optical devices, circularly polarizes the incoming light.

Snapshot taken by SLAC’s high-speed electron camera, an instrument for ultrafast electron diffraction (MeV-UED), showing evidence of circular polarization of terahertz light by an ultrathin sample of tungsten ditelluride. (Sie et al., Nano Letters, 8 May 2024)

While taking snapshots with the high-speed electron camera at the Department of Energy’s SLAC National Acceleratory Laboratory, researchers discovered new behavior in an ultrathin material that offers a promising approach to manipulating light that will be useful for devices that detect, control or emit light, collectively known as optoelectronic devices, and investigating how light is polarized within a material. Optoelectronic devices are used in many technologies that touch our daily lives, including light-emitting diodes (LEDs), optical fibers and medical imaging.

As reported in Nano Letters, the team, led by SLAC and Stanford professor Aaron Lindenberg, found that when oriented in a specific direction and subjected to linear terahertz radiation, an ultrathin film of tungsten ditelluride, which has desirable properties for polarizing light used in optical devices, circularly polarizes the incoming light.

Terahertz radiation lies between the microwave and the infrared regions in the electromagnetic spectrum and enables novel ways of both characterizing and controlling the properties of materials. Scientists would like to figure out a way to harness that light for the development of future optoelectronic devices.

Up to 3% of people with diabetes have an allergic reaction to insulin. A team at Forschungszentrum Jülich has now studied a method that could be used to deliver the active substance into the body in a masked form—in the form of tiny nanoparticles.

The insulin is only released in the target organ when the pH value deviates from the slightly alkaline environment in the blood. The molecular transport system could also serve as a platform for releasing other drugs in the body precisely at the target site.

It’s an old dream in pharmacy: To deliver an active ingredient to the exact place in the body where it is most needed—a cancer drug, for example, directly to the tumor tissue. This minimizes its side effects on other organs and ensures that it has its maximum effect at its target.

Humanoids, robotic or virtual systems with body structures that resemble the human body, have a wide range of real-world applications. As their limbs and bodies mirror those of humans, they could be made to reproduce a wide range of human movements, such as walking, crouching, jumping, swimming and so on.

Computationally generating realistic motions for virtual humanoid characters could have interesting implications for the development of video games, animated films, virtual reality (VR) experiences, and other media content. Yet the environments portrayed in video games and animations are often highly dynamic and complex, which can make planning motions for humanoids introduced in these environments more challenging.

Continue reading “A new model to plan and control the movements of humanoids in 3D environments” »